pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,638 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT834Endpoints639BioPharma Dive243onclive165BioSpace98Fierce Biotech96raps37globenewswire health28fda recalls
therapy area
allOncology5001Rare Disease846Cardiology797Hematology768Immunology732Psychiatry & CNS582Pulmonology570Vaccines
  • Pfizer's Albert Bourla says he has no mega-merger plans
    The most candid man in pharma strikes again. When asked on Tuesday’s earnings call whether Pfizer would consider a “transformative M&A” deal in the near or medium term, CEO Albert Bourla said it wo…
    Endpoints · 2mo ago↗ source
  • HS-10504 Shows Promising Activity in EGFR C797S–Mutant NSCLC After TKI Resistance
    Phase 1 data show HS-10504 yields encouraging responses and manageable safety in EGFR C797S–mutant NSCLC post TKI therapy.
    onclive · 2mo ago↗ source
  • STAT+: Pharma’s reputation among patient groups rose last year, but concerns remain over access and pricing
    The pharma industry saw its reputation among patient groups inch up last year, a new survey finds, but concerns remain over access and pricing.
    STAT
← prev
page 57 of 66
next →
22
fda press21
fda medwatch17
516
Endocrinology & Metabolism290
Ophthalmology255
Infectious Disease253
Nephrology238
· 2mo ago
↗ source
  • STAT+: A new attack on AMA’s billing codes
    A key GOP lawmaker is broadening the party's efforts to combat health care fraud.
    STAT · 2mo ago↗ source
  • BioNTech to scale down manufacturing, over 1,800 jobs on the line
    BioNTech is making big cuts to its manufacturing footprint. The German company said in its first-quarter earnings release that up to 1,860 manufacturing staff could be impacted by its planned downs…
    Endpoints · 2mo ago↗ source
  • Parsley Health goes in-network nationwide
    When I first heard about Parsley Health close to a decade ago, the startup embodied a few trends I was following closely: primary care startups and cash-pay healthcare. For a ...
    Endpoints · 2mo ago↗ source
  • Breast Cancer Experts Preview Abstracts to Watch at the 2026 ESMO Breast Cancer Congress
    Experts in a range of breast cancer subtypes highlight research data being presented at the 2026 ESMO Breast Cancer Congress.
    onclive · 2mo ago↗ source
  • The Type of Fat—Not the Amount—Fuels Pancreatic Cancer
    Research from Yale Cancer Center showed that the type of fat consumed may matter more than amount in pancreatic cancer.
    onclive · 2mo ago↗ source
  • Second life for gene therapy; Takeda Phase 2/3 win; UK cancer biotech's $83M
    A blood test might predict who will respond to Wegovy; Viridian's thyroid eye disease drug wins another Phase 3; Ideaya drops two GSK-returned assets. 🧬 Second life for a gene therapy: A Cleveland…
    Endpoints · 2mo ago↗ source
  • Swiss manufacturing, biotech industry so far unfazed by geopolitics
    BASEL, Switzerland — Pharma manufacturing in Switzerland appears to be unperturbed by the threat of tariffs, but it might take several years before the impact of companies moving production to the…
    Endpoints · 2mo ago↗ source
  • Pfizer ends Trillium-related development as R&D spend jumps
    Pfizer has discontinued the final clinical study stemming from its 2021 acquisition of Trillium Therapeutics, funneling cash primarily toward a host of other cancer and obesity studies. The company…
    Endpoints · 2mo ago↗ source
  • STAT+: Are analysts too quick to gloss over Lilly’s liver case?
    Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The Readout
    STAT · 2mo ago↗ source
  • Microbiome startup raises $48M for immunotherapy and malnutrition treatments
    Scientists trying to understand why cancer immunotherapy works so well for some patients and not others have found a potential answer in one cancer survivor's poop. A biotech startup has studied th…
    Endpoints · 2mo ago↗ source
  • J&J's IBD combo fails Phase 2 studies, but will move into pivotal testing
    Johnson & Johnson will move a treatment for inflammatory bowel disease into Phase 3 studies despite the therapy's failure in two mid-stage trials. The company said that JNJ-4804, a combination of t…
    Endpoints · 2mo ago↗ source
  • Iopofosine I 131 Follow-Up Data Show Strong Efficacy in Waldenström Macroglobulinemia
    Iopofosine I 131 produced strong responses in Waldenström macroglobulinemia, according to 12-month folllow-up data from CLOVER WaM requested by the FDA.
    onclive · 2mo ago↗ source
  • Dr McGregor on Key End Points of the STRIKE Trial of Tivozanib Plus Pembrolizumab in RCC
    Bradley McGregor, MD, discusses the end points that will be evaluated in the phase 3 STRIKE trial of adjuvant tivozanib plus pembrolizumab in high-risk RCC.
    onclive · 2mo ago↗ source
  • Madrigal extends MASH deal streak with Arrowhead drug that J&J didn't want
    Madrigal Pharmaceuticals has made its fourth MASH deal in 10 months, further signaling its ambitions to be not just the first drugmaker for the fatty liver disease, but also the owner of the field'…
    Endpoints · 2mo ago↗ source
  • Healthcare organizations are increasingly building their own AI tools
    Big healthcare organizations are increasingly building their own AI tools, rather than shelling out for tools made by health tech startups that may eventually become free. It’s not uncommon to find…
    Endpoints · 2mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about RFK Jr. targeting antidepressants, J&J pushing an IBD drug, and more
    HHS Secretary Robert F. Kennedy Jr. announced initiatives to rein in prescribing of SSRIs, the most widely used antidepressants
    STAT · 2mo ago↗ source
  • Dr Kuykendall on the Evolving JAK Inhibitor and Transplant Considerations in Myelofibrosis
    Andrew Kuykendall, MD, explains considerations for JAK inhibitor sequencing and the use of transplant in myelofibrosis.
    onclive · 2mo ago↗ source
  • New Endometrial Targets Beyond HER2
    Interest in endometrial cancer extends well beyond HER2, and the faculty review a growing pipeline of antibody drug conjugates directed at additional targets. Discussion includes why TROPE2 and oth…
    onclive · 2mo ago↗ source
  • Coordinating Care in Multiple Myeloma Across Practice Settings
    onclive · 2mo ago↗ source
  • EGFR-Mutated NSCLC: Molecular Reassessment at Disease Progression
    In this case-based segment, Dr. Sands presents a patient with EGFR-mutated metastatic non-small cell lung cancer who has progressed after first-line combination therapy with an EGFR tyrosine kinase…
    onclive · 2mo ago↗ source
  • New Understandings of Treatments, End Points, and Disease Biology Expand MCL Horizons
    Lore Gruenbaum, PhD, discusses the direction mantle cell lymphoma is headed in addition to other critical areas of unmet needs.
    onclive · 2mo ago↗ source
  • What you need to know about hantavirus (don’t panic)
    The latest on the abortion pill, paternal deaths, and more health news from Morning Rounds
    STAT · 2mo ago↗ source